May 17, 2011 - Medrad Inc., a business of Bayer HealthCare, today announced it has received CE Mark for its Cotavance Paclitaxel Coated Balloon Angioplasty Catheter with Paccocathtechnology. The Cotavance catheter is used in percutaneous interventions for the treatment of peripheral arterial disease (PAD) and is approved for balloon dilation of stenotic lesions in the iliac and infrainguinal arteries while applying paclitaxel to the vessel wall to inhibit restenosis. Medrad Interventional has started selling its Cotavance catheter in countries where it has already received regulatory approval, including select European and Middle East countries. The announcement was made in conjunction with the Congress of the European Association of Percutaneous Cardiovascular Interventions (EuroPCR) in Paris.
